viewOptiBiotix Health PLC

OptiBiotix Health enters precision nutrition field with Spanish LPLDL licensing deal

IENP has developed a test that analyses gut bacteria, the results from which it uses to place customers on a targeted food supplement regime to help boost their microbiome

The deal gives IENP non-exclusive rights to use LPLDL in its products

A Spanish foods giant has signed a licensing agreement to use OptiBiotix Health PLC’s (LON:OPTI) cholesterol and blood pressure-reducing LPLDL strain in some of its products.

The agreement gives Instituto Español de Nutrición Personalizada (IENP) non-exclusive rights to manufacture and market food supplements containing LPLDL in Spain for the next three years.

IENP is the precision nutrition branch of CAPSA Food, one of Spain’s largest food conglomerates which turns over more than €700mln a year.

READ: Opti sets launch date for weight management product

It has developed a test that analyses gut microbiome – the bacteria living in the intestine – which it then uses to place customers on different, targeted food supplement regimes to help get their microbiome back to healthy.

Under the terms of the deal, IENP will use its network to market the product in supermarkets, department stores, pharmacies, and online across Spain.

“We are delighted to enter the field of personalised and precision nutrition, one of the fastest-growing and highest-value sectors within the food industry,” said OptiBiotix’s business development director, Luis Gosálbez.

“Within two years of launch, we now have products being sold by numerous partners in over 30 countries around the world.

“We see this agreement as another step to growing revenues, market presence, and brand value of LPLDL, the 'Intel' inside a wide range of products in consumer and pharmaceutical markets around the world.”

Quick facts: OptiBiotix Health PLC

Price: 61.5 GBX

Market: AIM
Market Cap: £52.55 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of OptiBiotix Health PLC named herein, including the promotion by the Company of OptiBiotix Health PLC in any Content on the Site, the Company...



OptiBiotix's Stephen O'Hara hails new safety status for LPLDL and recent awards

OptiBiotix Health PLC’s (LON:OPTI) Stephen O'Hara speaks to Proactive London's Andrew Scott soon after the news its LPLDL probiotic had been granted ‘generally recognised as safe’ (GRAS) status by the US Food and Drug Administration (FDA). Its subsidiary, ProBiotix Health Ltd, received the...

3 weeks ago

2 min read